Last reviewed · How we verify
Pazopanib plus capecitabine
Pazopanib plus capecitabine is a Small molecule drug developed by GBG Forschungs GmbH. It is currently in Phase 1 development.
At a glance
| Generic name | Pazopanib plus capecitabine |
|---|---|
| Sponsor | GBG Forschungs GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors (PHASE1)
- Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer (PHASE1)
- Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin) (PHASE1)
- A Study of Pazopanib With CAPEOX in AGC Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pazopanib plus capecitabine CI brief — competitive landscape report
- Pazopanib plus capecitabine updates RSS · CI watch RSS
- GBG Forschungs GmbH portfolio CI
Frequently asked questions about Pazopanib plus capecitabine
What is Pazopanib plus capecitabine?
Pazopanib plus capecitabine is a Small molecule drug developed by GBG Forschungs GmbH.
Who makes Pazopanib plus capecitabine?
Pazopanib plus capecitabine is developed by GBG Forschungs GmbH (see full GBG Forschungs GmbH pipeline at /company/gbg-forschungs-gmbh).
What development phase is Pazopanib plus capecitabine in?
Pazopanib plus capecitabine is in Phase 1.
Related
- Manufacturer: GBG Forschungs GmbH — full pipeline
- Compare: Pazopanib plus capecitabine vs similar drugs
- Pricing: Pazopanib plus capecitabine cost, discount & access